SDOG250117C59000
- 0.00
- 0.000.00%
Alps Etf Trust Sector Dividend Dogs Etf Newsroom
Famous Analyst warns: the Technology bubble is approaching a "critical point", be wary of large hedge funds selling off.
Kaplan, the CEO of True Contrarian blog and newsletter, believes that the current technology bubble in U.S. stocks has grown larger... the current bear market may have already begun. He also stated that if stocks like QQQ drop by 20%, those funds worth trillions of dollars will sell off at the same time.
Looking Into AbbVie's Recent Short Interest
Investigate China's chips? A USA group suggests caution.
Recently, the Semiconductors Industry Association (SIA) released the following statement from SIA President and CEO John Neuffer regarding the Biden administration's decision to launch a Section 301 trade investigation, focusing on China's behaviors, policies, and practices aimed at dominating the Semiconductors Industry.
AI Agent, the next stop for large model implementation.
AI Agent is an intelligent agent that can perceive the environment, autonomously plan, make decisions, and execute actions to achieve goals, possessing essential characteristics such as autonomy, interactivity, reactivity, and adaptability, with large language models as its core driving force. With breakthroughs in underlying technologies powered by large models, we are seeing AI Agents gradually implemented in focused vertical + multiple agent collaborative application scenarios. According to market.us, the Global large model market size is expected to grow from 4.5 billion dollars in 2023 to 82.1 billion dollars by 2033, with a 10-year CAGR of 33.7%. We are Bullish about the future development trend of AI Agents and the investment opportunities brought by changes in the upstream and downstream Industry Chain.
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
The list of preferred chip stocks for 2025 has been revealed! In addition to NVIDIA and Broadcom, Wall Street's major firms are also bullish on these companies.
Analysts at Bank of America expect the overall sales of the Semiconductors market to grow by about 15% in 2025, building on the strong growth projected for 2024, reaching 725 billion dollars. Although this growth rate is slower compared to this year's forecast of 20%, it remains very strong and robust.
American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back
American Airlines Resumes Flights in the U.S. and Averts the Southwest Airlines Holiday Meltdown of 2022
Saying one thing and doing another? Europe's imports of Russian LNG have reached a record high.
The EU vows to eliminate its dependence on Russian chemical fuels, but ultimately cannot resist the temptation of Low Stock Price. However, to appease Trump, Europe may increase imports from the USA going forward.
Pfizer (PFE.US) cancer small molecule combination therapy has received accelerated approval from the FDA.
Pfizer (PFE.US) recently announced that the USA FDA has expedited the approval of the BRAF inhibitor Braftovi (encorafenib) in combination with Erbitux (cetuximab) and the mFOLFOX6 treatment regimen (which includes fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been tested positive for the BRAF V600E mutation.
Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.
Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Analyst Expectations For Darden Restaurants's Future
Morgan Stanley Maintains Overweight on Darden Restaurants, Raises Price Target to $209
2024's 'Biggest Loses' That Could See Reversal in 2025
Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials
Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment
Too much increase! Hedge Funds are starting to reduce their holdings in USA Nuclear Power stocks.
Recently, with the strong rebound of Nuclear Power stocks, some hedge fund managers have started to be cautious about their high valuations and have reduced their exposure to Nuclear Power stocks. However, Guy Keller, the portfolio manager at Tribeca, also stated that he would never establish short positions.
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More